A new coronavirus vaccine could be on the way, but there are still some questions about the effectiveness of the vaccine, experts say.
The U.S. Centers for Disease Control and Prevention is set to announce Tuesday that it is working on a new coronivirus vaccine, which it hopes to begin testing in 2019.
But how effective the vaccine would be, and if it will be effective in fighting the virus, remains in doubt.
The vaccine is expected to cost about $100 billion.
The coronaviruses first hit the U.K. and France in the early 2020s, killing more than 8,000 people, mostly children.
In the U: British Prime Minister Theresa May, left, talks to Prime Minister of France Emmanuel Macron during a news conference in London, Britain, on May 23, 2020.
In France: French President Emmanuel Macron delivers a speech during the opening session of the National Assembly of the Republic of the French Republic at the National Palace in Paris, France, on June 4, 2020, a day after the French government announced it would launch a vaccine campaign to protect the population against the coronaviral pandemic.
The new coronaval vaccine will be developed in collaboration with a consortium of international vaccine makers.
The government has promised to give the new vaccine to the public in 2019, a year before the current coronavillas vaccine.
A large amount of the money for the new coronavais vaccine has been spent on testing, developing and testing the new vaccines.
The government says it will spend up to $500 million for testing and testing.
But the U.-French team is working from a different source, and it is not clear how effective it is at testing the vaccine against the current virus.
The United States is one of the few countries that has not had a vaccine produced.
So far, the U-S.
government has not announced how many doses of its vaccine it will send to Europe.
A study published in the journal Nature by two researchers from the University of Pennsylvania and the Johns Hopkins University looked at the effectiveness against coronavills in the U., and it found the vaccine did not do as well as the current vaccines.
They found that the vaccine produced antibodies against the virus that were too weak to protect against the vaccine.
The researchers did find that the current vaccine did protect against both the new and old coronavides, but the vaccine was not effective in preventing infection in humans.
In a press release, the researchers said the vaccine does not have any advantage over the current U.N. vaccine, and that it could be difficult to manufacture in a safe way.
The study was published in The Lancet.
The WHO said in a statement that the study “shows that the effectiveness and safety of the current and future vaccines is questionable.”